Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 7/20 | 0.71 |
| ▸ | PTGS1 | P23219 | 5/20 | 0.71 |
| ▸ | FLT1 | P17948 | 3/20 | 0.71 |
| ▸ | FLT4 | P35916 | 3/20 | 0.71 |
| ▸ | KDR | P35968 | 3/20 | 0.71 |
| ▸ | MEN1 | O00255 | 1/20 | 0.71 |
| ▸ | LMNA | P02545 | 1/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.71 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.71 |
| ▸ | EGFR | P00533 | 4/20 | 0.61 |
| ▸ | BLM | P54132 | 1/20 | 0.57 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | MMP1 | P03956 | 1/20 | 0.56 |
| ▸ | MMP2 | P08253 | 1/20 | 0.56 |
| ▸ | MMP9 | P14780 | 1/20 | 0.56 |
| ▸ | MMP8 | P22894 | 1/20 | 0.56 |
| ▸ | MMP13 | P45452 | 1/20 | 0.56 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24347999 | 0.93 | PTGS2 (0.67) | PTGS2PTGS1FLT1FLT4KDR | |
| SCHEMBL174010 | 0.87 | FLT1 (0.77) | PTGS2PTGS1FLT1FLT4KDR | |
| Potassium SCHEMBL30358590 | 0.85 | FLT1 (0.74) | PTGS2PTGS1FLT1FLT4KDR | |
| SCHEMBL29011132 | 0.85 | FLT1 (0.74) | PTGS2PTGS1FLT1FLT4KDR | |
| SCHEMBL8424044 | 0.84 | FLT1 (0.73) | PTGS2PTGS1FLT1FLT4KDR | |
| SCHEMBL5931288 | 0.83 | FLT1 (0.71) | PTGS2PTGS1FLT1FLT4KDR | |
| SCHEMBL7367486 | 0.83 | PTGS2 (0.68) | PTGS2PTGS1FLT1FLT4KDR | |
| SCHEMBL5931087 | 0.83 | PTGS2 (0.71) | PTGS2PTGS1FLT1FLT4KDR | |
| Sulfabenzamide SCHEMBL93841 | 0.83 | KMT2A (1.00) | PTGS2PTGS1FLT1FLT4KDR | |
| SCHEMBL28698398 | 0.83 | PTGS2 (0.71) | PTGS2PTGS1FLT1FLT4KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114059090-B | Preparation method of benzo [ e ] [1,4,3] oxathiazine-1, 1-dioxide derivative | 福州大学 | 2023-11-21 | — | — | CN | disclosed |
| CN-114059090-A | Preparation method of benzo [ e ] [1,4,3] oxathiazine-1, 1-dioxide derivative | 福州大学 | 2022-02-18 | — | — | CN | disclosed |
| US-7629366-B2 | Aminoalcohol derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-08 | — | — | US | disclosed |
| US-7446222-B2 | Phenyl compounds | GLAXO GROUP LIMITED (GB) | 2008-11-04 | — | — | US | disclosed |
| US-20060235057-A1 | Phenyl compounds | GLAXO GROUP LIMITED (GB) | 2006-10-19 | — | — | US | disclosed |
| CN-1802355-A | Aminoalcohol derivatives | FUJISAWA PHARMACEUTICAL CO (JP) | 2006-07-12 | — | — | CN | disclosed |
| US-20060100252-A1 | Aminoalcohol derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-11 | — | — | US | disclosed |
| US-7037938-B2 | Aminoalcohol derivatives | ASTELLAS PHARMA INC. (JP) | 2006-05-02 | — | — | US | disclosed |
| EP-1556330-A2 | PHENYL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2005-07-27 | — | — | EP | disclosed |
| EP-1546086-A2 | AMINOALCOHOL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004039753-A2 | PHENYL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2004-05-13 | — | — | WO | disclosed |
| US-20040006143-A1 | For therapy of urinary incontinence | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-01-08 | — | — | US | disclosed |
| WO-2004002939-A2 | AMINOALCOHOL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-01-08 | — | — | WO | disclosed |
| EP-0189305-A2 | Peptide derivatives | ICI AMERICAS INC. (US) | 1986-07-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060235057-A1 | Phenyl compounds | RXRB, CYP2C9, RXFP1 | PTGS2 2262/4885PTGS1 1686/4885FLT1 1427/4885 |
| US-20060100252-A1 | Aminoalcohol derivatives | H1-0, CHRM2, CHRM1 | PTGS2 3088/4885PTGS1 2713/4885FLT1 4151/4885 |
| US-20040006143-A1 | For therapy of urinary incontinence | H1-0, HRH2, H1-2 | PTGS2 1311/4885PTGS1 1072/4885FLT1 4557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.